Ff6ntmhbr7mtygb2afh2 diag

DIAG2TEC

No Reviews Yet
No Completed Orders
Montpellier, FR

About DIAG2TEC

Diag2Tec is a preclinical CRO devoted to Hematological Malignancies, especially Multiple Myeloma (MM).


We focus on in vitro Drug Testing in Multiple Myeloma, Lymphoma, Leukemia derived Cell Lines and Primary Cells from patients. With our Drug Testing Services and ChimioFx Platforms, our mission is to provide efficient treatment solutions and precision medicine tools for patients suffering from Hematological Malignancies. We support biotech and pharmaceutical companies to focus their preclinical drug development on the right molecules in the right indications.

Our Services (10)


ic

Drug Discovery & Development

Price on request
Request a quote for more information about this service.

ic

Exome Sequencing Services

Price on request
Request a quote for more information about this service.

ic

RNA-Seq Data Analysis

Price on request
Request a quote for more information about this service.

ic

Next Generation Sequencing (NGS)

Price on request

In recent years, Next Generation Sequencing (NGS) studies of hematological malignancies have allowed a finer characterization of the cancer cells underlying these diseases by further highlighting their heterogeneity and revealing novel molecular alterations. Our team has developed different tools and algorithms to analyze these data and answer to specific medical challenges.


ic

Omics

Price on request
Request a quote for more information about this service.

ic

Flow Cytometry

Price on request

Flow cytometry is widely used for the diagnosis and monitoring of hematological disorders including multiple myeloma. We have developed different approaches of multiparameter flow cytometry to detect various malignant and normal plasma cells, B and T lymphocytes, NK cells, hematopoietic stem cells…

We can combine these approaches with BrDU incorporation or Ki67 staining to analyze tumoral or normal cell proliferation in various cell lines or in samples from patients with different hematological cancers.

Cells are analyzed using our cytometer (Beckman Coulter’s CytoFlex, 3 lasers, 12 colors).

Diag2Tec uses also a cell sorter (FACS Aria) to isolate and recover one or more cell population(s) according to size, granularity or fluorescence parameters.


ic

Drug Mechanism of Action Studies

Mechanism of Action Studies
Price on request

With our fully characterized cell lines, Diag2Tec offers you the possibility to investigate drug resistance and associated mechanisms of action. We can search if there is a correlation between the sensitivity of cells to the therapeutic agent investigated and the mutational status of genes commonly involved in multiple myeloma, lymphoma and leukemia. We can also investigate in our cell lines, a potential correlation of your therapeutic agent sensitivity with NFkB index, the molecular subgroup of patients, chromosomal abnormalities… In addition, we can compare Gene Expression Profiling of sensitive and resistant cells to the therapeutic agent treatment by SAM (Significance Analysis of Micro-arrays) and/or by LIMA analyses and with RNAseq data.

These studies allow to identify activated or modulated pathways following treatment with a given drug and to select other drugs that could be paired with the therapeutic agent investigated for the best synergistic combination therapies.


ic

In vitro Drug Efficacy Testing

Price on request

To investigate the hematological cancer cell lines response to various anti-cancer drugs including targeted, chemotherapies and immunotherapies alone or in combination, we propose you to measure the cell growth inhibition. We use a Cell Titer Glo Luminescent Assay to quantify this cell growth inhibition and we determine the median inhibitory concentration (IC50) of each cell lines using GraphPad Prism.
We can also use the different inhibitors IC50 already evaluated in our panel of cell lines and compare to your specific inhibitor.

Our cell lines have been thoroughly characterized using microarrays, RNA-seq, Exome-seq, SNP analysis, DNA methylation analysis, miRNA and Chip-seq. In addition, immunophenotypic and cytogenetic characterization of all HMCLs have been carried out. In addition, we offer you the possibility to investigate drug resistance and associated mechanisms of action.


ic

ADCC and CDC Assays

Price on request

We propose you to investigate the in vitro autologous or heterologous (with NK from healthy donor enrichment) cytotoxicity of your antibodies using cell lines or primary cells from patients with hematologic malignancies. For this experiment, we culture the primary cells with their bone marrow environment to best replicated the in vivo cytotoxicity of antibodies.

With the multi-parametric flow cytometry, we can simultaneously identify and analyze the effect of antibodies in various subpopulations of cells: normal and abnormal primary cells, T and B lymphocytes and NK cells. We can investigate the absolute number these cells in the different conditions. Additionally, we offer you the quantification of a target antigen in tumoral cells by Specific Antibody Binding Capacity assay (SABC).


ic

Biomarker Discovery

Price on request

To identify biomarkers predictive of hematological cancer cells to a given drug, we use RNA seq and Exome seq data generated with cell lines and primary cells from patients treated with the drug. Then, we select genes deregulated by the inhibitor in the different conditions and genes associated with a prognostic value in patients (using our independent cohorts of patients with hematological malignancies). Finally, the identification of Biomarkers is constructed using our patented methodologies.

Biomarkers associated with cancer cells response to a given inhibitor treatment can be validated using assays in additional primary cells from patients with hematological malignancies.


Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.

DIAG2TEC has not received any reviews.

DIAG2TEC has not received any endorsements.